R9Q.F RECCE PHARMACEUTICALS LTD

Healthcare Biotechnology Frankfurt Exchange
0.2020 EUR
Close of Nov 12, 2026
0.1490 0.4500
Market cap
EUR 61.8M
P/E
-
P/B
159.49x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is R9Q.F undervalued?

Graham number

The Graham number of RECCE PHARMACEUTICALS LTD cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RECCE PHARMACEUTICALS LTD fundamental analysis

No fundamental analysis for RECCE PHARMACEUTICALS LTD yet.

RECCE PHARMACEUTICALS LTD stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RECCE PHARMACEUTICALS LTD

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical…

Full company profile